Role of a combination dietary supplement containing mucopolysaccharides, vitamin C, and collagen on tendon healing in rats

Halil Can Gemalmaz, Kerim Sarıylmaz, Okan Ozkunt, Seren Gulsen Gurgen, Sena Silay

Acibadem University School of Medicine, Istanbul, Turkey
Celal Bayar University School of Vocational Health Services, Department of Histology and Embryology, Manisa, Turkey

Abstract

Objective: The aim of this study was to investigate the effect of mucopolysaccharide, vitamin C, and collagen supplementation on the healing of Achilles tendon in rats.

Methods: Sixteen rats were separated into 2 groups. Both Achilles tendons of all rats were transected 5 mm above the insertion and repaired using a Kessler suture. After the surgical repair, the study group received the daily recommended amount of the supplement by gastric gavage, while the control group received a placebo. At the end of the third week, the animals were sacrificed. The biomechanical properties of the groups were compared with ultimate tensile strength and stiffness tests. The biological properties of the 2 groups were assessed with a histomorphometric comparison to determine the amount of collagen type I (COL1), proliferating cell nuclear antigen (PCNA), and transforming growth factor β1 (TGF-β1) expression in 3 different tissue subgroups (collagen matrix, tenocytes, and endotenon fibroblasts).

Results: Analysis of histomorphometric results revealed that the rats receiving dietary supplements demonstrated a significant increase in PCNA (mean value of 86 in the control group and 168.85 in the trial group; p < 0.05) and TGF-β1 (mean value of 87.57 in the control group and 161.85 in the trial group; p < 0.05) in the endotenon fibroblasts of the repair site. However, there was no difference between the groups in PCNA or TGF-β1 when the collagen matrix and the tenocytes of the repair site were examined. Furthermore, no significant difference could be found between groups in COL1 in any of the 3 tissue subgroups (collagen matrix, tenocytes, and endotenon fibroblasts). The statistical analysis also indicated that the rats receiving supplements did not demonstrate a significant increase in the ultimate tendon tensile strength or stiffness.

Conclusion: The results of this study revealed no advantage to the oral administration of the trial supplement in collagen synthesis or biomechanical properties in rats after 3 weeks using the presented study design. However, the increased expression of PCNA and TGF-β1 seen in the endotenon fibroblasts of the repair site might play a role in the continuum of tendon healing.

Introduction

Tendon injury is a common problem with a wide range of clinical and pathological presentations. The spectrum of tendon injury includes simple synovitis of the tendon sheet at 1 end to complete rupture from degeneration at the other end. Nevertheless, the main pathology is believed to be physical strain surpassing the regenerative capacity of the tendon. The treatment approach ranges from simple rest, ice, and anti-inflammatory medication, to splinting or surgical repair, mainly depending on the amount of...
degeneration and the tendon’s physical integrity level. Physical therapy plays an important role in some resistant cases and after surgical treatment of tendon ruptures. Steroid injections have been employed for tendonitis cases with varied results and with drawbacks. In the last decade, some new treatment options have been advocated, such as platelet-rich plasma injections, prolotherapy, and dry needling, with very controversial results. Along with these minimally invasive, yet debated new treatment options, a variety of dietary supplements have also been advocated in recent years for a variety of orthopedic disorders. The most renowned are mucopolysaccharides and collagen supplements.

Unlike the well-established and accepted effects of vitamin and mineral supplements like vitamin D, vitamin C, and calcium on the musculoskeletal system, the literature focusing on musculoskeletal wellbeing is not very strong in legitimate data on dietary supplements. To our knowledge, there is no report of regarding a deficiency of mucopolysaccharides, but it is known that the level of some subgroups decreases with aging. There are also studies that report favorable outcomes for tendon pathologies with oral supplementation of mucopolysaccharides. Since collagen is a protein widely available in a standard Western diet, supplementation in someone who is on a regular diet can be argued. There is also some literature evidence correlating supplementation of collagen with endogenous upregulation of collagen synthesis. Some studies even report that collagen administered with vitamin C might have synergistic benefits on mesenchymal tissue and collagen synthesis.

Nevertheless, the literature is still weak in providing crystalized data regarding the benefits of these supplements to mesenchymal tissue metabolism and there seems to be very little interest in providing further data in the research community. Since many physicians, including orthopedic surgeons, do not hesitate to ask their patients to use some sort of supplement for conditions including tendon pathologies, the problem also becomes an ethical issue. The lack of solid evidence in these arguments should provoke the interest of orthopedic community toward research of musculoskeletal dietary supplements.

The combination of mucopolysaccharides, vitamin C, and collagen is an example of such supplementation that is widely recommended and prescribed, yet there are insufficient data confirming its effects. It is offered under many different generic names and in varied doses. The effects of a generic preparation combining mucopolysaccharides (220 mg), vitamin C (30 mg), and hydrolyzed collagen type I (COL1) (40 mg) in the severed and repaired tendon of a rat model was analyzed in this study.

Materials and methods

Approval to perform the study was obtained from the local ethics committee.

Sixteen skeletally mature male Wistar albino rats (aged 6 months and weighing 250–300 g), obtained from the direct source of the local animal experiments laboratory were used in this study to decrease genetic variability. After the proper induction of ketamine (100 mg/kg; Alfasan International, Woerden, Holland) anesthesia, both Achilles tendons of all animals were transected 5 mm proximal to the point of insertion to the calcaneus (Figs. 1 and 2). The Achilles tendon was repaired using 6/0 Prolene monofilament polypropylene (Ethicon, Inc., Somerville, NJ, USA) sutures with a modified Kessler method (Fig. 3). The plantaris tendon was protected to act as an internal splint to decrease tension at the repair site. The wound was closed with 3/0 Vicryl glycolide/L-lactide (Ethicon, Inc., Somerville, NJ, USA) absorbable uninterrupted sutures. No wound dressing or casting was used after the operation. All of the subjects were left to mobilize freely and were fed with...
standard laboratory food and tap water. One rat from the control group was lost right after the operation, probably due to an anesthesia-related complication.

All 8 rats in the study group were administered 2.4 mg of a trial supplement (7.2 mg/kg) by means of gastric gavage every day for 3 weeks. The dose was calculated based on the daily recommended dose for a person weighing 80 kg (2 capsules of 290 mg is recommended for adults with no adjustment for weight). On the fourth day after the surgical procedure, 1 rat from the study group was lost, leaving both groups with equal sample size of 7 rats. The control group received gastric gavage with an equal amount of tap water to control bias for any possible nutritional effects that the long-term gavage might cause. After the third week, all of the animals were sacrificed with a lethal dose of ketamine, which was administered intraperitoneally. Above-knee amputation was performed and the right legs of the animals were fresh frozen and reserved for biomechanical testing. The left legs of the animals were kept in 10% formalin solution and were reserved for histomorphometric tests.

**Histological method**

After extraction of the Achilles tissues from the preserved left legs, the tissues were fixed using neutral formalin solution for 24 h. Following routine histological procedures, the tissues were embedded in paraffin blocks. A total of 105 sections were obtained from each sample, each 5 μm in thickness. Hematoxylin–eosin stain was applied for regular examination and Masson’s trichrome stain (Bio-Optica Milano S.p.A, Milan, Italy) was applied for better visualization of collagen fibers.

To assess the tendon healing process with objective criteria, immune histochemical staining for COL1, proliferating cell nuclear antigen (PCNA), and transforming growth factor β 1 (TGF-β1) was performed. To further assess the possible location of biological activity related to the test variable, the strength of the staining was recorded in 3 different tissue areas: the collagen matrix, tenocytes, and endotenon fibroblasts. An Olympus microscope (CX31; Olympus Corp., Tokyo, Japan) with an attached camera and image analysis software (Leica Q Win V3 Plus Image; Leica Camera AG, Wetzler, Germany) was used for immune histochemical quantification. Every 10th section of the 105 serial sections was reserved for quantitative histological analysis (a total of 10 sections for each dye). First a semi-quantitative H-score (\(\sum \Pi (i + 1)\)) was calculated for each section by defining the density and percentage of expression for COL1, PCNA, and TGFβ1 in the different tissue subtypes (collagen matrix, tenocytes, and endotenon fibroblasts). In this equation, \(i\) is the intensity of labeling (1, 2, or 3 for weak, moderate, or strong, respectively) and \(\Pi\) is the percentage of labeled cells (0%–100%). The H-scores were summed to get a final, single value for each dye.

**Biomechanical method**

The fresh frozen right legs of the animals were thawed at standard room temperature. The mounting of the Achilles tendons to the test device was performed using the method described by Probst et al. The muscles proximal to the Achilles tendon are scraped from the tendon’s fascia with a scalpel. The tendon fibers are then fixed between strips of blotting paper to prevent slippage and clamped with a pair of solid blocks, which are later mounted on the mechanical test device. The distal calcaneus is osteotomized to leave the tuber calcaneus intact. A solid block with a pit just big enough to house the osteotomized calcaneus is prepared. Later, the tuber calcaneus is placed into the pit of the block, which is then mounted on the test device (Fig. 4). An Acumen 1 Electrodynamic Test System (MTS Systems Corp., Eden Prairie, MN, USA) mechanical testing device was used for the biomechanical assessment. A preload of 2 N was applied to adjust for equal pretension between all tendons. Later, continuous traction with 10 mm/min constant speed was applied to the tendons to define stiffness and ultimate tensile strength (Fig. 5).

**Statistical method**

All statistical analysis was performed with IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp., Armonk, NY, USA). Distribution of the data was tested using the Shapiro–Wilk test, skew, and kurtosis values, and was determined to be normal. Since the sample sizes were too small to be analyzed with a parametric test, the Mann–Whitney U test was used to statistically test the null hypothesis with a 95% confidence interval.

**Results**

The mean value for the ultimate tensile strength was found to be 25.29 ± 8.43 N for the study group and 22.18 ± 6.78 N for the control group. The mean stiffness value was 13.06 ± 4.69 N/mm for study group and 12.40 ± 4.50 N/mm for the control group. Statistical analysis of the biomechanical testing revealed that there was no significant difference between the study group, which was administered the trial supplement, and the control group in terms of ultimate tensile strength (\(p = 0.48\)) or stiffness of the tissues \((p = 0.65)\). Table 1 summarizes these data for easy visualization.
Subjective microscopic examination of the hematoxylin-eosin-stained tendon sections revealed that both groups were similar in the number of new blood vessels, fibroblasts, and quantity of connective tissue within the endotendineum. Gross examination also indicated that the quantity of tenocytes and collagen fibers within the fascicles of the tendon was similar (Fig. 6). Examination of the Masson’s trichrome sections revealed that both groups were comparable in collagen fiber density and configuration (Fig. 7).

The quantized results of the immune histochemical staining performed for COL1, PCNA, and TGF-β1 in the collagen matrix, tenocytes, and endotenon fibroblasts are summarized in this paragraph. The mean value of COL1 in the collagen matrix, tenocytes, and endotenon fibroblasts in the study group was $93.85 \pm 14.87$, $114.85 \pm 13.04$, and $113.42 \pm 19.76$, respectively, and for the control group it was $98 \pm 13.95$, $112.14 \pm 12.85$, and $130 \pm 12.31$, respectively. The mean value of PCNA in the collagen matrix, tenocytes, and endotenon fibroblasts in the study group was found to be $62.14 \pm 8.27$, $140.28 \pm 9.56$, and $168.85 \pm 14.84$, respectively, and $63 \pm 3.91$, $134 \pm 10.77$, and $86 \pm 7.07$, respectively, in the control group. Finally, the mean value of TGF-β1 in the collagen matrix, tenocytes, and endotenon fibroblasts in the study group was determined to be $63 \pm 9.39$, $94.85 \pm 16.30$, and $161.85 \pm 11.95$, respectively, and for the control group it was $62.71 \pm 8.69$, $91.85 \pm 12.33$, and $87.57 \pm 17.11$, respectively (Table 1).

The Mann–Whitney U test interpretation revealed no significant difference between the study group, which was given the trial supplement, and the control in any of the histological subgroups (p value of 0.14 for collagen matrix, 0.94 for tenocytes, and 0.09 for endotenon fibroblasts) in COL1 expression values. The comparison of PCNA expression showed a significant difference between the study and control groups in the endotenon fibroblasts but not in the tenocytes or collagen matrix (p-value for endotenon fibroblasts <0.05, p-value for collagen matrix = 0.74, and p-value for tenocytes = 0.24). Finally, analysis of TGF-β1 expression between groups revealed a significant difference in the endotenon fibroblasts, but no difference in the collagen matrix or tenocytes (p-value for endotenon fibroblasts <0.05, p-value for collagen matrix = 0.89, and p-value for tenocytes = 0.65). Table 1 summarizes these data for easy visualization.

Based on these results, at the end of the third week, the level of PCNA and TGF-β1 were greater in the endotenon fibroblasts but not in the collagen matrix or the tenocytes of the repair zone. The amount of COL1 was not significantly different between the study and the control group in any tissue/cell subgroup. Similarly, there was no difference in the ultimate tensile strength or stiffness between the group that was administered the trial supplement and the placebo group.

**Discussion**

Successful treatment of tendon pathologies remains challenging even in the modern era. New techniques, materials, and stem cell therapies are still being researched with the goal of achieving better outcomes. Along with these efforts, the medical community should also pay attention to dietary supplementation options. This area has been neglected by the research community. Most of these supplements lack robust scientific data to support their effects. The

---

**Table 1**

| Dependent variable | Study group Mean value | Standard deviation | Control group Mean value | Standard deviation | Mann–Whitney U | U Sig. (2-tailed) |
|--------------------|-----------------------|--------------------|--------------------------|--------------------|----------------|------------------|
| UTS (N)            | 25.29                 | 8.43               | 22.18                    | 6.78               | 3.11           | 0.48             |
| Stiffness (N/mm)   | 13.06                 | 4.69               | 12.4                     | 4.5                | 0.66           | 0.65             |
| Collagen matrix    |                       |                    |                          |                    |                |                  |
| COL1               | 93.85                 | 14.87              | 98                       | 13.95              | –4.15          | 0.14             |
| PCNA               | 62.14                 | 8.27               | 63                       | 3.91               | –0.86          | 0.74             |
| TGFβ1              | 63                    | 9.39               | 62.71                    | 8.69               | 0.29           | 0.89             |
| Tenocytes          |                       |                    |                          |                    |                |                  |
| COL1               | 114.85                | 13.04              | 112.14                   | 12.85              | 2.71           | 0.94             |
| PCNA               | 140.28                | 9.56               | 134                      | 10.77              | 6.28           | 0.24             |
| TGFβ1              | 94.85                 | 16.3               | 91.85                    | 12.33              | 3              | 0.65             |
| Endotenon fibroblasts |                 |                    |                          |                    |                |                  |
| COL1               | 113.42                | 19.76              | 130                      | 12.31              | –16.58         | 0.09             |
| PCNA               | 168.85                | 14.84              | 86                       | 7.07               | 82.85          | 0.002            |
| TGFβ1              | 161.85                | 11.95              | 87.57                    | 17.11              | 74.28          | 0.002            |

Bold defines statistically significant results.
The trial supplement used in this study was one of these diet supplements that have been suggested to enhance tendon healing in both tendinitis-related conditions and after tendon surgery. However, this claim is very poorly demonstrated in the literature. As a serious, randomized, controlled, in vivo animal trial, we believe that our study adds some of the missing data regarding this issue. We believe this is one of the strengths of our research.

PCNA is a nuclear protein that is known to affect DNA replication and repair and the cell cycle. Therefore, expression of PCNA is known to increase during tissue repair, where cellular proliferation and reproduction take place. It has been demonstrated in other studies that synovial border paratenon, endotenon, and aggressive fibroblasts play a critical role in tendon healing. It has also been shown that the number of PCNA-positive cells increases in the tendon repair zone. These PCNA-positive cells are thought to be cells differentiated from mesenchymal stem cells that migrate from the paratenon's synovial border to more central healing zones in the tendon tissue. TGF-β is accepted as one of the key proteins that seem to regulate tissue repair and collagen synthesis in connective tissue, though TGF-β1 expression is
affected by many factors and displays variability throughout the healing continuum.21−33

Our findings revealed potential benefits from the trial supplement, in that we found significantly higher PCNA and TGF-β1 levels in the endotenon fibroblasts in the study group at the end of the third week. Similar elevated levels were not observed in the tenocytes or collagen matrix. To our knowledge, there are no literature data with which to compare these findings, but it is easy to provide a reason for PCNA and TGF-β1 not showing elevated expression in the collagen matrix. Since PCNA is a nuclear antigen and TGF-β1 is predominantly an autocrine protein, they may not have increased expression in the extracellular matrix where collagen is deposited. We believe that different levels of PCNA and TGF-β1 in the tenocytes may have been a result of the yet-hypothetical fact that the trial supplement does not affect the tenocytes, at least at the third week in rats. This needs to be confirmed by additional studies.

The meaning of increased PCNA and TGF-β1 expression in the endotenon fibroblasts has yet to be discovered, since our study did not show a significant difference between groups in COL1 accumulation in the repair zone. This is also confirmed by the insignificant biomechanical test results for ultimate tensile strength and stiffness. The reason for these seemingly conflicting results may be numerous.

First, we cannot be sure that the stimulated endotenon fibroblasts are differentiated from synthesized collagen at the end of the third week. Even though most of the collagen deposition has occurred in the repair zone by the third week, we have no data to show that supplements such as we used in this research increase or speed up collagen synthesis. To better understand this, new studies investigating the trial supplement's effect at different time periods must be conducted to determine PCNA and TGF-β1 behavior throughout the continuum of tendon healing.

Secondly, pronounced expression of PCNA and TGF-β1 might not have resulted in increased collagen synthesis because this study was modeled on healthy, non-deficient rats (not deficient in any of the supplement's ingredients). Biological behavior might be totally different in the case of a deficient animal model, but to our knowledge there are no proven deficient animal models or reported deficiency for any of our trial supplement's ingredients, except vitamin C. It is known that in-vitro fibroblast cultures treated with vitamin C exhibit increased synthesis of COL1.34,35 It has also been reported in several animal studies that administration of a very high dose of vitamin C results in an increase in collagen density in the mesenchymal tissue.36−38 But these studies differ from ours in the amount of vitamin C administered, which can be as much as 75−100 mg/kg per day. As a result, we can assume that any supplement targeting an increase in collagen synthesis through the known effects of vitamin C should have meticulous dose-effect studies and possibly intoxicated studies as well.

Furthermore, the literature includes complex and confounding proof on TGF-β1 and its role in collagen synthesis. Tsubone et al31 reported extensive variability in TGF-β1 expression in different time periods in TGF-β1 inducible early gene (TIEG) knockout mice (TIEG is the first step in the TGF-β1 action pathway). They also showed that although TGF-β1 expression varied in TIEG knockout mice, COL1 synthesis continued, with a pattern identical to that of healthy mice. TIEG knockout mice do not have any problems regarding soft tissue healing. This indicates that there are other cytokines that regulate collagen synthesis aside from TGF-β1. Other studies have also mentioned that the role of TGF-β1 in collagen synthesis is not very well understood and that there are other responsible cytokines that have regulatory roles in collagen synthesis.39,40

Conclusion
Our research on rats revealed no difference in the group given the trial supplement (a combination of mucopolysaccharides, vitamin C, and COL1) in mechanical strength or the amount of collagen deposited at the repair site at the end of the third week. Since these are primary outcomes for tendon pathologies, we can conclude that the trial supplement provided no significant advantage in tendon healing using this methodology. On the other hand, we did note activation of fibroblasts in the repair site through increased expression of PCNA and TGF-β1. We have provided an initial explanation, but we believe further studies approaching this issue with a different methodology are needed to explain the nature of this cellular stimulation throughout the continuum of tendon healing.

Conflicts of interest
None of the authors have any potential conflict of interest to be disclosed.

References
1. Langberg H, Skoggaard D, Arp S, Kjaer M. Time pattern of exercise-induced changes in type I collagen turnover after prolonged endurance exercise in humans. Calcif Tissue Int. 2000 Jul;67(1):41−44. https://doi.org/10.1007/s002220010194.
2. Dunham J, Butts R, Mourad F, Young I, Flannagan S, Perreault T. Dry needling: a literature review with implications for clinical practice guidelines. Phys Ther Rev. 2014 Aug;19(4):252−265. https://doi.org/10.1179/1083193X13y.134425102034.
3. Rabago D, Lee KS, Ryan M, et al. Hypertonic dextrose and mornhuate sodium injections (prolotherapy) for lateral epicondylitis (Tennis elbow): results of a single-blind, pilot-level randomized controlled trial. Am J Phys Med Rehabil. 2013 Jul;92(7):587−596. https://doi.org/10.1097/PHM.0b013e318276969f.
4. Sanderson LM, Breyant A. Effectiveness and safety of prolotherapy injections for management of lower limb tendinopathy and fasciopathy: a systematic review. J Foot Ankle Res. 2015 Oct;8:57. https://doi.org/10.1186/s13047-014-0114-5, eCollection 2015.
5. Best TM, Zgierska AE, Zeisig E, Ryan M, Drake C. A systematic review of four injection therapies for lateral epicondylitis: prolotherapy, povidocanol, whole blood and platelet rich plasma. Br J Sports Med. 2009 Jul;43(7):471−481. https://doi.org/10.1136/bjsports.2008.052761.
6. Jeong DU, Lee CR, Lee JH, et al. Clinical applications of platelet-rich plasma in patellar tendinopathy. Biomed Res Int. 2014 Jul;2014:249498. https://doi.org/10.1155/2014/249498.
7. Merolla G, Dellabiancia F, Ingardia A, Paladin P, Porcellini G. Co-analgesic therapy for arthroscopic supraspinatus tendon repair pain using a dietary supplement containing Boswellia serrata and curcuma longa: a prospective randomized placebo-controlled study. Musculoskeletal Surg. 2013 Sep;99(suppl 1):S34−S52. https://doi.org/10.1016/j.muss.2013.06.036-1 [Epub 2015 May 10].
8. Notarnicola A, Pesce V, Vicentì G, Tafari S, Forcignano M, Moretti B. SWAAT study: extracorporeal shock wave therapy and arginine supplementation and other nutraceuticals for insertional Achilles tendinopathy. Adv Ther. 2012 Sep;29(9):799−814. https://doi.org/10.1007/s12325-012-0046-4 [Epub 2012 Aug 24].
9. Guminia S, Passaretti D, Gurzi MD, Candela V. Arginine L-alpha-ketoglutarate, methylsulfonylmethane, hydrolyzed type I collagen and bromelain in rotator cuff tear repair: a prospective randomized study. Curr Med Res Opin. 2012 Nov;28(11):1767−1774. https://doi.org/10.1185/03007995.2012.737773 [Epub 2012 Oct 19].
10. Sundqvist H, Forsskall B, Kvist M. A promising novel therapy for Achilles peritendinitis: double-blind comparison of glycosaminoglycan polysulfate and high-dose indomethacin. Int J Sports Med. 1987 Aug;8(4):296−303.
11. Shakibaei M, Buhrmann C, Mobasheri A. Anti-inflammatory and anti-catabolic effects of TENDOACTIVE® on human tenocytes in vitro. Histol Histopathol. 2011 Sep;26(9):1173−1185. https://doi.org/10.14670/HHP.2011.26.1173.
12. Usha PR, Naidu ML. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest. 2004 Jun;24(6):353−363. https://doi.org/10.2165/00044011-200424060-00005.
13. Buhrmann C, Mobasher A, Busch F, et al. Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2011 Aug;286(12):28556–28566. https://doi.org/10.1074/jbc.M111.256180 [Epub 2011 Jun 13].

14. Kubasaki T, Takahashi M, Asai Y, et al. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidosis and mucolipidoses. Mol Genet Metab. 2017 Mar;120(3):247–254. https://doi.org/10.1002/mgm.12101.

15. Shimada T, Tomatsu S, Yasuda E, et al. Chondroitin-6-sulfate as a novel biomarker for mucopolysaccharidosis IIIA and VII. JIMD Rep. 2014 May;16:15–24. https://doi.org/10.1007/8894_2014_311. Published online 2014 May 22.

16. Takeda K, Atago K, Hanano K, et al. The proliferating cell nuclear antigen (PCNA) as a marker for the in vivo proliferation of tenocytes. Connect Tissue Res. 2007 Nov;48(4):285–290. https://doi.org/10.1080/10908600701531177.

17. Probst A, Palmes D, Freise H, Langer M, Joist A, Spiegel HU. A new clamping technique for biomechanical testing of tendons in small animals. J Invest Surg. 2000 Nov-Dec;13(6):313–318.

18. Kubasaki T, Suzuki Y, Orii K, et al. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidosis and mucolipidoses. Mol Genet Metab. 2017 Mar;120(3):247–254. https://doi.org/10.1002/mgm.12101.

19. Shimada T, Tomatsu S, Yasuda E, et al. Chondroitin-6-sulfate as a novel biomarker for mucopolysaccharidosis IIIA and VII. JIMD Rep. 2014 May;16:15–24. https://doi.org/10.1007/8894_2014_311. Published online 2014 May 22.

20. Shaw G, Lee-Barthel A, Ross ML, Wang B, Baar K. Vitamin C-enriched gelatin supplementation before intermittent activity augments collagen synthesis. J Orthop Res. 2015 Oct;33(10):1435–1443. https://doi.org/10.1002/jor.22462. 2015 Sep 22.

21. Sato Y, Mera H, Takahashi D, et al. Synergistic effect of ascorbic acid and glucosamine-chondroitin sulfate on remodeling stage of tenomized superficial digital flexor tendon in rabbits: a clinical, histopathological, ultrastructural, and biomechanical study. Connect Tissue Res. 2010 Nov;52(4):325–339. https://doi.org/10.1080/10908601003008207.2010.531332.

22. Lippiello L. Collagen synthesis in tenocytes, ligament cells and chondrocytes exposed to a combination of glucosamine HCl and chondroitin sulfate. Evid Based Complement Alternat Med. 2007 Jun;4(2):219–224. https://doi.org/10.1093/ecam/neol081.

23. Chen MH, Huang YC, Sun JS, Chao YH, Chen MH. Second messengers mediating cation, repair and cell cycle control. In: Laurent M, Silvana G, Michel P, eds. J Cell Biochem Suppl. 1996;26(2):77–83. https://doi.org/10.1006/jcbi.2015.17.

24. Probst A, Palmes D, Freise H, Langer M, Joist A, Spiegel HU. A new clamping technique for biomechanical testing of tendons in small animals. J Invest Surg. 2000 Nov-Dec;13(6):313–318.

25. Kelman Z. PCNA: structure, functions and interactions. Oncogene. 1997 Feb 13;14(6):629–640.

26. Prosperti E. Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control. In: Laurent M, Silvana G, Michel P, eds. Progress in Cell Cycle Research. vol. 3. Boston: Springer; 1997:193–210. https://doi.org/10.1007/978-1-4615-5171-7_15.

27. Khan U, Ocleoten NI, Khaw PT, McGruther DA. Differences in proliferative rate and collagen lattice contraction between endotenon and synovial fibroblasts. J Hand Surg [Am]. 1998 Mar;23(2):266–273. https://doi.org/10.1016/S0363-5023(98)80125-1.

28. Khan U, Kakar S, Akali A, Bentley G, McGrouther DA. Modulation of the formation of adhesions during the healing of injured tendons. J Bone Joint Surg Br. 2000 Sep;82(7):1054–1058. https://doi.org/10.1302/0301-620X.82B7.0821054.

29. Tokunaga T, Shikumami C, Okamoto N, et al. FGF-2 stimulates the growth of tenogenic progenitor cells to facilitate the generation of tenomulin-positive tenocytes in a rat rotator cuff healing model. Am J Sports Med. 2015 Oct;43(10):2411–2422. https://doi.org/10.1177/0363546515597488 [Epub 2015 Aug 26].

30. Dyment NA, Hagierta Y, Matthews BG, Li Y, Kalazic I, Rowe DW. Lineage tracing of resident tendon progenitor cells during growth and natural healing. PloS One. 2014 Apr 23;9(4):e96113. https://doi.org/10.1371/journal.pone.0096113. eCollection 2014.

31. Tsubone T, Moran SL, Subramaniam M, Amadio PC, Spelsberg TC, An KN. Effect of TGF-beta inducible early gene deficiency on flexor tendon healing. J Orthop Res. 2006 Mar;24(3):569–575. https://doi.org/10.1002/jor.20101.

32. O’Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol. 1997 Jan;29(1):63–78. https://doi.org/10.1016/S1074-2647(96)00120-3.

33. Beck LS, Deguzman L, Lee WP, et al. TGF-beta 1 accelerates wound healing: reversal of steroid-impaired healing in rats and rabbits. Growth Factors. 1991;5(4):295–304.

34. Tajima S, Pinnell SR. Ascorbic acid preferentially enhances type I and III collagen gene expression in human skin fibroblasts. J Dermatol Sci. 1995 Mar;11(3):250–253. https://doi.org/10.1016/0923-1815(95)00640-0.

35. Kishimoto Y, Saito N, Kurita K, Shimokado K, Maryama N, Ishigami A. Ascorbic acid enhances the expression of type I and type 4 collagen and SVCT2 in cultured human skin fibroblasts. Biochem Biophys Res Commun. 2013 Jan 11;440(2):579–584. https://doi.org/10.1016/j.bbrc.2012.11.110.

36. Omeregu H, Peker T, Turukozan N, Omeregu H. High-dose vitamin C supplementation accelerates the Achilles tendon healing in healthy rats. Arch Orthop Trauma Surg. February 2009;129(2):281–286. https://doi.org/10.1007/s00402-008-0603-0 [Epub 2008 Feb 28].

37. Danielski LG, Walczewski E, de Jesus CR, et al. Preoperative vitamin C supplementation improves colorectal anastomotic healing and biochemical parameters in malnourished rats. Int J Colorectal Dis. 2016 Nov;31(11):1759–1766. https://doi.org/10.1007/s00395-016-2047-x.

38. Findik RB, Ikaya F, Guresci S, Guzel H, Karabulut S, Karakaya J. Effect of vitamin C on collagen structure of cardinal and uterosacral ligaments during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2016 Jun;210:31–35. https://doi.org/10.1016/j.ejogrb.2016.03.022.

39. Blobe GC, Schiennam WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000 May;342(4):1350–1358. https://doi.org/10.1056/NEJM200005043412107.

40. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999 Sep;341(10):738–746. https://doi.org/10.1056/NEJM199909023411006.